Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Hyperion Therapeutics (San Francisco, CA) a clinical-stage specialty pharmaceutical company focused on gastroenterology and hepatology, closed a $60M Series C financing. Participants include Bay City Capital, Panorama Capital, Highland Capital Partners, New Enterprise Associates, Sofinnova Ventures, and WRF Capital.

Alios BioPharma (San Francisco, CA) a preclinical-stage small molecule and protein therapeutics company focused on viral disease via innate immune modulation, closed a $8M Series A financing bring the total round to $32M. Participants include SR One, Novo Ventures, Novartis Venture Fund and Roche Venture Fund.

Anulex Technologies (Minnetonka, MN) a commercial-stage medical device company focused on herniated discectomy procedures, closed a $10.2M Series D financing. Participants include Affinity Capital, Delphi Ventures, MB Venture Partners, New Enterprise Associates, SightLine Partners and Split Rock Partners.

Stentys (France) a clinical-stage medical device company focused on stents designed for treatment of acute myocardial infarction and coronary artery bifurcations, closed a $4.2M Series B financing bringing the round total to $22.2M. Participants include Crédit Agricole Private Equity, Sofinnova Partners and Scottish Equity Partners.

Interlace Medical (Framingham, MA) a near commercial-stage gynecological medical device company focused MIS removal of intrauterine fibroids and polyps, closed a $20M Series C financing. Participants include Baird Venture Partners, HLM Venture Partners, Hambrecht & Quist Capital Management, Aperture Venture Partners, New Leaf Venture Partners and Spray Venture Partners.

CeNeRx BioPharma (Cary, NC) a clinical-stage biopharmaceutical company focused on diseases of the central nervous system, closed a $4M Series C financing. Participants include Aisling Capital, L Capital Partners and Pappas Ventures.

Intrexon (Blacksburg, VA) a clinical-stage biopharmaceutical company focused on modular inducible cancer immunotherapeutics, closed a $10M Series C bring the total round financing to date of $35M. Participants include New River Management.

Catheter Connections ( Park City, UT) an early-stage focused on accessory products for the prevention of infection in the vascular catheter access device market, closed a $1.3M Series A financing. Participants include vSpring Capital and Kickstart Seed Fund.

Taris Biomedical (Lexington, MA) a preclinical-stage drug:device company focused on interstitial cystitis, close a $15M Series A financing. Participants include Flagship Ventures, Flybridge Capital Partners and Polaris Venture Partners.

Aileron Therapeutics (Cambridge, MA) a pre-clinical large molecule biopharmaceutical company focused on oncology, inflammation and metabolic and infectious diseases, closed a $40M Series D financing. Participants include Excel Medical Ventures, SR One, Lilly Ventures, Roche Venture Fund, Apple Tree Partners and Novartis Venture Funds.

Zephyr Technology (Annapolis, MD) a commercial-stage device company focused on real-time monitoring of human of physiological and biomechanical conditions, closed a $2M Series B financing. Participants include Motorola Ventures.

SynCardia Systems (Tuscan, AZ) commercial-stage manufacturer of the temporary cardiowest total artificial heart, closed a $10.3M Series D financing. Participants include Highway 12 Ventures.

VytronUS (Sunnyvale, CA) a stealth, assumed early-stage cardiac medical device company focused on cardiology, closed an $11M Series B financing. Participants include Delphi Ventures and New Enterprise Associates.

« Previous Entries  Next Page »

to top of page...